GlassScriptPhysician profile
Rhonda Mose
NPI 1023433901
$3,511.58
in general payments reported to CMS, 2019-2025
27 companies · $1,853 in 2025
The $1,853 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $253 · 2024: $1,406 · 2025: $1,853.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,435 · Education: $76.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,434.59 |
| Education | $76.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $521.02 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $506.96 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $328.12 | 2024-2025 | |
| Novo Nordisk INC | $242.17 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $214.06 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $213.63 | 2023-2025 | Veozah, Myrbetriq |
| Harmony Biosciences LLC | $189.41 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $162.00 | 2024-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $146.53 | 2024-2025 | Caplyta |
| Exact Sciences Corporation | $116.54 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Abbvie INC. | $114.59 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $111.90 | 2023-2025 | |
| Shield Therapeutics INC | $93.82 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $84.36 | 2023-2025 | Xifaxan |
| Sumitomo Pharma America, INC. | $70.72 | 2023-2025 | Gemtesa |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.49 | 2024-2025 | Jardiance, Synjardy, Tradjenta |
| Aimmune Therapeutics, INC. | $56.50 | 2024-2025 | Zenpep, Vowst |
| Merck Sharp & Dohme LLC | $45.11 | 2024-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Corcept Therapeutics | $37.86 | 2025 | Korlym |
| Idorsia Pharmaceuticals US INC | $34.68 | 2024 | Quviviq |
| Amgen INC. | $30.44 | 2023-2025 | Repatha, Otezla, Repatha |
| Phathom Pharmaceuticals, INC. | $30.37 | 2025 | Voquezna |
| Insulet Corporation | $24.38 | 2025 | Omnipod |
| Antares Pharma, INC. | $19.44 | 2025 | Xyosted |
| Novartis Pharmaceuticals Corporation | $17.23 | 2025 | |
| Lundbeck LLC | $16.95 | 2025 | Rexulti |
| Dexcom, INC. | $13.30 | 2024 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rhonda Mose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.